Retrospective Survey of Bone Fracture in Patients With Arimidex 1mg

AstraZeneca2,205 enrolled

Overview

The retrospective survey is to investigate the incidence of bone fracture in post-menopausal breast cancer patients with Arimidex 1mg, who were previously registered for the clinical experience investigation.

Study Type

OBSERVATIONAL

Enrollment

2,205

Conditions

Breast Cancer

Eligibility

Sex: FEMALE

Medical Language ↔ Plain English

Inclusion Criteria: * Post-menopausal breast cancer patients treated with Arimidex 1mg at the time of previously conducted clinical experience investigation. Exclusion Criteria: \-

Outcomes

Primary Outcomes

Bone fracture incidence

Time frame: Time since starting Arimidex

Secondary Outcomes

Survival

Time frame: Time since starting Arimidex

Bone density measurement

Time frame: Time since starting Arimidex

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.